All posts tagged "GILD"
-
2.9KBiotechCytoDyn’s Adjust Course to Emphasize Philippine EUA and Long Haulers
Many CytoDyn Inc. (OTCMKTS: CYDY) shareholders have been waiting impatiently for an EUA from the US FDA and a BLA in HIV. ...
-
5593BiotechCytoDyn Saves Lives & Reduces COVID-19 Hospital Duration
6 endpoints met after full data release so shorts double down on trial failure narrative Investors in CytoDyn Inc. (OTCMKTS: CYDY) are...
-
1.0KBiotechRISE of the COVID-19 Therapeutics CytoDyn (OTCMKTS: CYDY) & Humanigen (NASDAQ:HGEN)
Enrollment Key Metric in Therapeutic Race Philippines EUA Relevant to CytoDyn, not Humanigen Highly Credentialed Humanigen Team Possibility of NAS...
-
3651BiotechCytoDyn (OTCMKTS: CYDY) Accelerates Recruitment to 250 Patients in Pivotal COVID-19 Trial
CytoDyn Inc. (OTCMKTS:CYDY) on a conference call yesterday revealed that approximately 250 patients have been recruited in their CD12 severe to cri...
-
12.6KBiotechHandicapping CytoDyn’s (OTCMKTS: CYDY) Interim Readout
Powerful recommendation from DSMB Imminent on Leronlimab Numbers are not part of any Interim report unless a statistical penalty is taken A...
-
6042BiotechWading through the STAT News FUD Attack on CytoDyn Inc. (OTCMKTS: CYDY)
CytoDyn Inc. (OTCMKTS: CYDY) announced superb top-line data in their mild to moderate COVID-19 phase 2 trial and did not disappoint; however,...
-
2.3K1BiotechCytoDyn’s (OTCMKTS: CYDY) Strong Safety Data in Mild to Moderate Smokes Gilead (NASDAQ: GILD) & Crushes Endpoint Leading to the First Potential COVID-19 Approval
CytoDyn Inc. (OTCMKTS: CYDY) announced groundbreaking safety results from its phase 2 Mild to Moderate COVID-19 trial today. The company reported ...
-
14.7K1BiotechCytoDyn (OTCMKTS: CYDY) Bolts Higher On Mexican Approval Chatter
Yesterday CytoDyn Inc. (OTCMKTS: CYDY) moved up 27% on the completion of a Memorandum of Understanding with the NIH of Mexico to...
-
4111BiotechGilead (NASDAQ: GILD) Shares Jump On Trial Results and Fauci Despite 9.3% Mortality Rate After 14 Days
Today Gilead Sciences (NASDAQ: GILD) was making a splash about their phase 3 trial results but all this trial essentially did was...
-
27.8KBiotechUK Prime Minister Boris Johnson Linkage to CytoDyn (OTCMKTS: CYDY) Evolving
CytoDyn Inc. (OTCMKTS: CYDY) announced today it was collaborating with the United Kingdom’s Department of Health to provide emergency access to ler...